ENBI — Entheon Biomedical Share Price
- CA$1.66m
- CA$1.14m
- 31
- 15
- 30
- 14
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 3.33 | ||
Price to Tang. Book | 3.33 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -80.79% | ||
Return on Equity | -95.32% | ||
Operating Margin | n/a |
Financial Summary
Year End 30th Nov | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CA$m | n/a | 0.02 | 0.19 | 0.25 | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Entheon Biomedical Corp. is a Canada-based biotechnology research and development company. The Company is interested in treating addiction and substance-use disorders.
Directors
- Last Annual
- November 30th, 2024
- Last Interim
- February 28th, 2025
- Incorporated
- April 6th, 2010
- Public Since
- May 3rd, 2018
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Canadian Securities Exchange
- Shares in Issue
- 13,858,934

- Address
- Suite 720-999 W Broadway Street, VANCOUVER, V5Z 1K5
- Web
- https://entheonbiomedical.com/
- Phone
- +1 6045623932
- Auditors
- Manning Elliott LLP
Upcoming Events for ENBI
Q2 2025 Entheon Biomedical Corp Earnings Release
Q3 2025 Entheon Biomedical Corp Earnings Release
Similar to ENBI
Albert Labs International
Canadian Securities Exchange
Algernon Pharmaceuticals
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
Awakn Life Sciences
Canadian Securities Exchange
BetterLife Pharma
Canadian Securities Exchange
FAQ
As of Today at 20:27 UTC, shares in Entheon Biomedical are trading at CA$0.12. This share price information is delayed by 15 minutes.
Shares in Entheon Biomedical last closed at CA$0.12 and the price had moved by -47.83% over the past 365 days. In terms of relative price strength the Entheon Biomedical share price has underperformed the Toronto Stock Exchange 300 Composite Index by -53.61% over the past year.
There is no consensus recommendation for this security.
Find out moreEntheon Biomedical does not currently pay a dividend.
Entheon Biomedical does not currently pay a dividend.
Entheon Biomedical does not currently pay a dividend.
To buy shares in Entheon Biomedical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.12, shares in Entheon Biomedical had a market capitalisation of CA$1.66m.
Here are the trading details for Entheon Biomedical:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: ENBI
Based on an overall assessment of its quality, value and momentum Entheon Biomedical is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Entheon Biomedical. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +13.62%.
As of the last closing price of CA$0.12, shares in Entheon Biomedical were trading -8.5% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Entheon Biomedical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Entheon Biomedical's directors